Gene therapy with cytokine coding DNA is effective tumor treatment. For systemic transgene release the muscle is suitable transfection site, enabling the controlled release. The study has demonstrated that this approach has good antitumor effect on local tumor growth and metastases, also in combination with tumor or metastases irradiation.
COBISS.SI-ID: 820091
We evaluated the antitumor effect of IL12 electrogene therapy on murine SA1 sarcoma. The IL12 plasmid was applied either intra or peritumorally. Intratumoral electrogene therapy resulted in 90% complete response rate to treatment with 60% resistance to challenge with SA1 tumor cells. Peritumoral electrogene therapy resulted in 16% complete response rate. Furthermore, significant growth delay of untreated tumors at a distant site was achieved. These data suggest that IL12 electrogene therapy may be useful in the treatment of soft tissue sarcomas
COBISS.SI-ID: 3131770
In this study, electrogene therapy (EGT) as a new therapeutic approach to canine MCTs, was established. Eight dogs with a total of eleven cutaneous MCTs were treated with intratumoral EGT using DNA plasmid encoding human interleukin12 (IL12). Intratumoral EGT with IL12 Elicits significant reduction of treated tumors’ size, ranging from 13% to 83% (median 50%) of the initial tumor volume. These data suggest that intratumoral EGT with plasmid encoding IL12 may be useful in the treatment of canine MCTs, exerting a local antitumor effect.
COBISS.SI-ID: 3270266
The review article is a comprehensive review of preclinical and clinical studies on IL12 electrogene therapy of cancer. The preclinical studies have demonstrated that IL12 gene elctrotransfer is an effective approach as local or systemic treatment. Translation of preclinical studies into clinical trials in human and veterinary oncology has started with encouraging results that would hopefully lead to further investigation of this therapy, also in combination with other cancer treatment modalities.
COBISS.SI-ID: 980859
The use of large animals as an experimental model for novel treatment techniques has many advantages over the use of laboratory animals, so veterinary medicine is becoming an increasingly important translational bridge between preclinical studies and human medicine. The results of preclinical studies show that gene therapy with therapeutic gene encoding interleukin-12 (IL-12) displays pronounced antitumor effects in various tumor models. A number of different studies employing this therapeutic plasmid, delivered by either viral or non-viral methods, have also been undertaken in veterinary oncology. In cats, adenoviral delivery into soft tissue sarcomas has been employed. In horses, naked plasmid DNA has been delivered by direct intratumoral injection into nodules of metastatic melanoma. In dogs, various types of tumors have been treated with either local or systemic IL-12 electrogene therapy. The results of these studies show that IL-12 based gene therapy elicits a good antitumor effect on spontaneously occurring tumors in large animals, while being safe and well tolerated by the animals. Hopefully, such results will lead to further investigation of this therapy in veterinary medicine and successful translation into human clinical trials.
COBISS.SI-ID: 1383803